Symptom Burden and Quality of Life Issues among Patients of Chronic Myeloid Leukemia on Long-term Imatinib Therapy

BACKGROUND: Tyrosine kinase inhibitors such as imatinib have improved survival in chronic myeloid leukemia (CML). Imatinib can cause chronic side effects which are not considered serious but can impact the quality of life (QoL) of the patient. METHODS: The results of a detailed symptom burden analys...

Descripción completa

Detalles Bibliográficos
Autores principales: Unnikrishnan, Radhika, Veeraiah, Surendran, Ganesan, Prasanth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5582554/
https://www.ncbi.nlm.nih.gov/pubmed/28900325
http://dx.doi.org/10.4103/ijmpo.ijmpo_160_16

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5582554/
https://www.ncbi.nlm.nih.gov/pubmed/28900325
http://dx.doi.org/10.4103/ijmpo.ijmpo_160_16

Ejemplares similares